# Interferon α 2b Pharmacovigilance Study

> **NCT01841775** · PHASE4 · COMPLETED · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 85 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** interferon α 2b + ribavirin

## Key facts

- **NCT ID:** NCT01841775
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2013-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01841775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01841775, "Interferon α 2b Pharmacovigilance Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01841775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*